Therefore, after confirming that approximately 75% of CD34+ mobilized peripheral blood progenitor cells from myeloma patients en route to SCT co-expressed CD38 (Fig. 1a, b), we sought to determine the number of CD38 molecules per CD34+ cell. This evidence concerns the gene CD38 and plasma cell myeloma.